| Vitas Healthcare Corporation Of California 990 W 190th Street, Suite 550, Torrance, CA, 90502 | |
| (310) 324-2273 |
News Archive
A third of patients thought to have resistant hypertension had "white coat" hypertension during 24-hour ambulatory monitoring, in a large study reported in Hypertension: Journal of the American Heart Association.
Most colorectal cancer develops from precursors known as polyps, the most common and well researched of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
› Verified 8 days ago
| Name | Vitas Healthcare Corporation Of California |
|---|---|
| Location | 990 W 190th Street, Suite 550, Torrance, California |
| Hospice ID | 051739 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 200 |
News Archive
A third of patients thought to have resistant hypertension had "white coat" hypertension during 24-hour ambulatory monitoring, in a large study reported in Hypertension: Journal of the American Heart Association.
Most colorectal cancer develops from precursors known as polyps, the most common and well researched of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
› Verified 8 days ago
| NPI Number | 1639213747 |
| Organization Name | Vitas Healthcare Corporation Of California |
| Address | 990 W 190th St Torrance, California, 90502 |
| Phone Number | (310)924-2273 |
News Archive
A third of patients thought to have resistant hypertension had "white coat" hypertension during 24-hour ambulatory monitoring, in a large study reported in Hypertension: Journal of the American Heart Association.
Most colorectal cancer develops from precursors known as polyps, the most common and well researched of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 95.4 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 92.9 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 77.1 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 76.4 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 95.1 | 97.3 |
| Patients who got timely treatment for shortness of breath | 98.7 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 98.1 | 93.3 |
News Archive
A third of patients thought to have resistant hypertension had "white coat" hypertension during 24-hour ambulatory monitoring, in a large study reported in Hypertension: Journal of the American Heart Association.
Most colorectal cancer develops from precursors known as polyps, the most common and well researched of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
› Verified 8 days ago
| Home Health Aides | 17 |
| Counselors | 3 |
| Homemakers | 1 |
| Licensed Practical or Vocational Nurses | 16 |
| Medical Social Workers | 3 |
| Physicians | 3 |
| Registered Nurses | 18 |
| Other Personnel | 19 |
| Total Employees | 80 |
|---|
News Archive
A third of patients thought to have resistant hypertension had "white coat" hypertension during 24-hour ambulatory monitoring, in a large study reported in Hypertension: Journal of the American Heart Association.
Most colorectal cancer develops from precursors known as polyps, the most common and well researched of which are conventional adenomas. Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.
› Verified 8 days ago
| Providence Trinitycare Hospice Location: 5315 Torrance Blvd., Torrance, California, 90503 Phone: (310) 324-2273 |
| Torrance Memorial Hospice Location: 23326 Hawthorne Blvd Suite 100 B, Torrance, California, 90505 Phone: (310) 324-2273 |
| Milestone Hospice, Inc Location: 1500 Crenshaw Blvd Suite 200, Torrance, California, 90501 Phone: (310) 324-2273 |
| Vitas Healthcare Corporation Of California Location: 990 W 190th Street, Suite 550, Torrance, California, 90502 Phone: (310) 324-2273 |